ReviewRetina (Philadelphia, Pa.)2020
CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.
Review in Retina (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3.Acta ophthalmologica · 2022Trial
- Bilateral choroidal thinning during unilateral aflibercept for neovascular age-related macular degeneration: 5-year mixed-effects analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Retinal Pigment Epithelium Changes in Pediatric Combined Hamartoma of the Retina and Retinal Pigment Epithelium: Wide-Field Swept-Source OCT Findings.Translational vision science & technology · 2026Article
- Advancing AMD screening with an offline, AI-powered smartphone-based fundus camera: A prospective, real-world clinical validation.Eye (London, England) · 2025Article
- A Systematic Review and Meta-Analysis Association Between Periodontitis and Age-Related Macular Degeneration: Potential for Personalized Approach.Journal of personalized medicine · 2025Review
- Assessment of optical coherence tomography biomarkers in patients with non-neovascular age-related macular degeneration (AMD) converting to exudative AMD according to the status of the fellow eye.Eye (London, England) · 2024Article
- Early Optical Coherence Tomography Biomarkers for Selected Retinal Diseases-A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes.BMC ophthalmology · 2023Article
- Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?Eye (London, England) · 2023Article
- Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2023Article
- What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register.Acta ophthalmologica · 2022Observational
- THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months.Retina (Philadelphia, Pa.) · 2022Article
- [Real-life results of anti-VEGF treatment in fellow eyes with nAMD].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Article
- Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses.European journal of ophthalmology · 2021Article
- Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Review
- Academic Ophthalmology during and after the COVID-19 Pandemic.Ophthalmology · 2020Article
- Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe presence of neovascular age-related macular degeneration (nAMD) in one eye is a major risk factor for the development of disease in the fellow eye. Several methods exist to help physicians monitor the fellow eye, with new technologies becoming increasingly available.
methodsWe provide an overview of modalities for nAMD monitoring, including advances in home-based options, and review their utility for fellow-eye monitoring, based on a review of the literature and a consensus of retinal experts.
resultsStudies demonstrate the importance of early detection of nAMD in the fellow eye so that interventions can be made before significant vision loss occurs. A series of techniques exist for the early detection of nAMD including chart-based methods and imaging devices. The increased availability of home-based methods has presented an opportunity for patients to monitor their vision at home.
conclusionFrequent monitoring of the fellow eye in patients with unilateral nAMD is of critical importance to prevent vision loss and maintain quality of life. Patients should be examined every 3 to 4 months from the time of choroidal neovascularization diagnosis and encouraged to monitor their vision at home using home-based technologies where available, to provide the best opportunity for early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.